Research Study

A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis
Principal Investigator 
Virginia A. Devonshire

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT01201356
Status 
Closed to Recruitment
Study Start/End 
Oct 1, 2010 to Jun 30, 2018
Locations 
UBC Hospital
Name/Title 
Karina Grigore, Research Coordinator
Phone 
604 827-1892
Email Address 
karina.grigore@ubc.ca
Purpose of Study 

The purpose of this study is to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study will combine all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that will provide patients with continuous treatment and will continue until fingolimod is registered, commercially available, and reimbursed in the respective countries.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.